Skip to main content

Table 6 Treatment-emergent adverse events occurred at similar rates in patients using and not using migraine preventive treatments

From: Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

TEAELasmiditan dose (mg)Using preventivesNot using preventives
n/N (%)n/N (%)
DizzinessPBO6/231 (2.6)31/1031 (3.0)
All LTN81/544 (14.9)385/2633 (14.6)
ParesthesiaPBO2/231 (0.9)17/1031 (1.6)
All LTN44/544 (8.1)136/2633 (5.2)
SomnolencePBO5/231 (2.2)22/1031 (2.1)
All LTN22/544 (4.0)153/2633 (5.8)
FatiguePBO2/231 (0.9)6/1031 (0.6)
All LTN16/544 (2.9)104/2633 (3.9)
NauseaPBO3/231 (1.3)17/1031 (1.6)
All LTN21/544 (3.9)86/2633 (3.3)
Muscular WeaknessPBO0/231 (0.0)0/1031 (0.0)
All LTN3/544 (0.6)39/2633 (1.5)
HypoesthesiaPBO1/231 (0.4)2/1031 (0.2)
All LTN3/544 (0.6)36/2633 (1.4)
  1. N number of patients in the subgroup of safety population, n number of patients with TEAE, TEAE treatment-emergent adverse event, All LTN, pooled population receiving lasmiditan (LTN) 50 mg, 100 mg, or 200 mg LTN
  2. Treatment-by-subgroup interaction did not indicate any statistically significant interaction for any TEAE (all interaction p-values > 0.1)
\